Gudlifer
🖕
- Joined
- Dec 22, 2025
- Posts
- 6,518
- Reputation
- 11,248
I saw a TikTok (don't even start) that mentioned Pazopanib (it's a Tyrosine Kynase Inhibitor, targeting VEGFR-1, -2, and -3, PDGFR-α and -β, c-Kit and FGFR).
Well the thing is that it's been show to DRAMATICALLY widen the growth plate:
Well the reason I'm posting this is because I would assume the widening comes from an arrest of hypertrophic zone ossification rather than a resting zone expansion and from my understanding this would not result in an increase in FAH.
IS THERE SOMETHING IM MISSING?
DO YOU HAVE ANY EXPERIENCE/ANECDOTES WITH IT AND WAS IT POSITIVE OR NEGATIVE??
Even if it worked I'd probably just use erda instead bc of risk profile and evidence but still, any anecdotes/knowledge on this would be appreciated
Well the thing is that it's been show to DRAMATICALLY widen the growth plate:
Well the reason I'm posting this is because I would assume the widening comes from an arrest of hypertrophic zone ossification rather than a resting zone expansion and from my understanding this would not result in an increase in FAH.
IS THERE SOMETHING IM MISSING?
DO YOU HAVE ANY EXPERIENCE/ANECDOTES WITH IT AND WAS IT POSITIVE OR NEGATIVE??
Even if it worked I'd probably just use erda instead bc of risk profile and evidence but still, any anecdotes/knowledge on this would be appreciated
Attachments
Last edited: